Journal
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
Volume 321, Issue 1, Pages L119-L129Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajplung.00639.2020
Keywords
drug response; elexacaftor; ivacaftor; organoids; tezacaftor
Categories
Funding
- National Institutes of Health (NIH) [K23HL143167]
- Cystic Fibrosis Foundation (CFF) [GUIMBE18A0-Q, GUIMBE1710]
- Gregory Fleming James Cystic Fibrosis Center [NIH] [R35HL135816, DK072482]
- CFF University of Alabama at Birmingham (UAB) Research and Development Program [Rowe19RO]
- UAB Center for Clinical and Translational Science (NIH) [UL1TR001417]
Ask authors/readers for more resources
An in vitro biomarker derived from patients' cells was used to predict drug responses in cystic fibrosis, showing correlation between organoid swelling assay and short-circuit current measurements. The organoid assay can distinguish individual and group responses, predicting clinical outcomes.
In vitro biomarkers to assess cystic fibrosis transmembrane conductance regulator activity are desirable for precision modulator selection and as a tool for clinical trials. Here, we describe an organoid swelling assay derived from human nasal epithelia using commercially available reagents and equipment and an automated imaging process. Cells were collected in nasal brush biopsies, expanded in vitro, and cultured as spherical organoids or as monolayers. Organoids were used in a functional swelling assay with automated measurements and analysis, whereas monolayers were used for short-circuit current measurements to assess ion channel activity. Clinical data were collected from patients on modulators. Relationships between swelling data and short-circuit current, as well as between swelling data and clinical outcome measures, were assessed. The organoid assay measurements correlated with short-circuit current measurements for ion channel activity. The functional organoid assay distinguished individual responses as well as differences between groups. The organoid assay distinguished incremental drug responses to modulator monotherapy with ivacaftor and combination therapy with ivacaftor, tezacaftor, and elexacaftor. The swelling activity paralleled the clinical response. In conclusion, an in vitro biomarker derived from patients' cells can be used to predict responses to drugs and is likely to be useful as a preclinical tool to aid in the development of novel treatments and as a clinical trial outcome measure for a variety of applications, including gene therapy or editing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available